Adeno-associated virus capsid antigen presentation is dependent on endosomal escape
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV) vectors are attractive for gene delivery-based therapeutics, but data from recent clinical trials have indicated that AAV capsids induce a cytotoxic T lymphocyte (CTL) response that eliminates transduced cells. In this study, we used traditional pharmacological agents and AAV mutants to elucidate the pathway of capsid cross-presentation in AAV-permissive cells. Endosomal acidification inhibitors blocked AAV2 antigen presentation by over 90%, while proteasome inhibitors completely abrogated antigen presentation. Using mutant viruses that are defective for nuclear entry, we observed a 90% decrease in capsid antigen presentation. Different antigen presentation efficiencies were achieved by selectively mutating virion nuclear localization signals. Low antigen presentation was demonstrated with basic region 1 (BR1) mutants, despite relatively high transduction efficiency, whereas there was no difference in antigen presentation between BR2 and BR3 mutants defective for transduction, as compared with wild-type AAV2. These results suggest that effective AAV2 capsid antigen presentation is dependent on AAV virion escape from the endosome/lysosome for antigen degradation by proteasomes, but is independent of nuclear uncoating. These results should facilitate the design of effective strategies to evade capsid-specific CTL-mediated elimination of AAV-transduced target cells in future clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, mutation of surface tyrosine has been suggested, which resulted in reduced presentation of AAV capsid, decreased T-cell toxicity, and required therapeutic dose [100, 225, 229].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [225]
Experimental — accuracy not yet measuredIn the citing paper
“In vitro and preclinical animal studies have shown administration of bortezomib prevents degradation of internalized AAVs, reduces capsid presentation, and increases transduction efficiency by enhancing nuclear translocation of AAV [165, 224, 225].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [225]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903 · cited 1×
“tion approach with the standard calcium phosphate protocol (56).”
Autophagy as a Regulated Pathway of Cellular Degradation
Klionsky, D. J., & Emr, S. D. (2000) · Science · doi:10.1126/science.290.5497.1717 · Cited by 3,608
Singh, R. P., Kurz, J., & Boiteau, G. (1996) · Journal of Virological Methods · doi:10.1016/0166-0934(96)02096-4 · Cited by 2,552
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“These include a phospholipase A2 (PLA2) motif and 3 basic regions (BR1, 2, and 3), all of which putatively con-trol endosomal escape, nuclear localization, and nuclear import via the nuclear pore complex, respectively (27–31).”
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Self-citationXiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381
Self-citationMaguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865 · cited 2×
“In a patient with hemophilia B, CTL-mediated elimination of transduced cells was observed at a later time point (4 weeks) after AAV delivery (1).”
αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection
Summerford, C., Bartlett, J. S., & Samulski, R. J. (1999) · Nature Medicine · doi:10.1038/4768 · Cited by 711
Self-citation
Cited by
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Self-citationHastie, E., & Samulski, R. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.025 · Cited by 280
Self-citationBucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Overcoming innate immune barriers that impede AAV gene therapy vectors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212
“However, these regulatory cassettes have been found to have leaky expression in DCs (140, 141). miRNA-mediated detargeting • Inclusion of binding sites for cognate miRNAs that have high levels of expression in APCs into vectors leads to degradation of transgene transcripts as a consequence of host miRNAs and results i…”
BackgroundInfluentialAdeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174
Self-citationGao, K., Li, M., Zhong, L., Su, Q., Li, J., Li, S., He, R., Zhang, Y., Hendricks, G., Wang, J., et al. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2013.9 · Cited by 165
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“Therefore, mutation of surface tyrosine has been suggested, which resulted in reduced presentation of AAV capsid, decreased T-cell toxicity, and required therapeutic dose [100, 225, 229].”
BackgroundAAV vectors applied to the treatment of CNS disorders: Clinical status and challenges
Kang, L., Jin, S., Wang, J., Lv, Z., Xin, C., Tan, C., Zhao, M., Wang, L., & Liu, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.067 · Cited by 131
Rogers, G. L., Shirley, J. L., Zolotukhin, I., Kumar, S. R. P., Sherman, A., Perrin, G. Q., Hoffman, B. E., Srivastava, A., Basner-Tschakarjan, E., Wallet, M. A., et al. (2017) · Blood · doi:10.1182/blood-2016-11-751040 · Cited by 131
“Endosomal escape is required for cross-presentation of capsid antigen by hepatocytes.(21,46,47) Removal of phosphorylation sites on the capsid reduces ubiquitination and thus MHC I presentation, thereby reducing the likelihood of transduced hepatocytes being targeted by CD8 T cells.”
Recombinant Adeno-Associated Virus Utilizes Host Cell Nuclear Import Machinery To Enter the Nucleus
Nicolson, S. C., & Samulski, R. J. (2014) · Journal of Virology · doi:10.1128/jvi.02660-13 · Cited by 114
Self-citationAdeno-Associated Virus (AAV) Versus Immune Response
Rabinowitz, J., Chan, Y. K., & Samulski, R. J. (2019) · Viruses · doi:10.3390/v11020102 · Cited by 122
“Proteasomes degrade ubiquitinated proteins into small peptide fragments that are, for the most part, too small to be taken into the endoplasmic reticulum (ER) by the transporter associated with antigen processing (TAP) [42].”
BackgroundSelf-citationJourney to the Center of the Cell: Tracing the Path of AAV Transduction
Dhungel, B. P., Bailey, C. G., & Rasko, J. E. J. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.09.010 · Cited by 122
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Yang, T., Braun, M., Lembke, W., McBlane, F., Kamerud, J., DeWall, S. L., Tarcsa, E., Fang, X., Hofer, L., Kavita, U., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.018 · Cited by 136
Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid
Vercauteren, K., Hoffman, B. E., Zolotukhin, I., Keeler, G. D., Xiao, J. W., Basner-Tschakarjan, E., High, K. A., Ertl, H. C., Rice, C. M., Srivastava, A., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.61 · Cited by 114
Hareendran, S., Balakrishnan, B., Sen, D., Kumar, S., Srivastava, A., & Jayandharan, G. R. (2013) · Reviews in Medical Virology · doi:10.1002/rmv.1762 · Cited by 113
Hanlon, D. J., Saluja, S. S., Sharp, F. A., Hong, E., Khalil, D., Tigelaar, R. E., Fahmy, T. M., Edelson, R. L., & Robinson, E. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s66639 · Cited by 120
Nonnenmacher, M. E., Cintrat, J.-C., Gillet, D., & Weber, T. (2015) · Journal of Virology · doi:10.1128/jvi.02520-14 · Cited by 95
Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions
Basner-Tschakarjan, E., & Mingozzi, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00350 · Cited by 95
The potential of adeno-associated viral vectors for gene delivery to muscle tissue
Wang, D., Zhong, L., Nahid, M. A., & Gao, G. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.871258 · Cited by 98
Ertl, H. C. J., & High, K. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.172 · Cited by 94
“71,72 Clinical trials for AAV-FIX transfer failed to show an increase in transgene product-specific T cells.”
Adeno-associated Virus as a Mammalian DNA Vector
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0052-2014 · Cited by 87
Self-citationShirley, J. L., Keeler, G. D., Sherman, A., Zolotukhin, I., Markusic, D. M., Hoffman, B. E., Morel, L. M., Wallet, M. A., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.011 · Cited by 79
Adeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 79
López-Gordo, E., Chamberlain, K., Riyad, J. M., Kohlbrenner, E., & Weber, T. (2024) · Viruses · doi:10.3390/v16030442 · Cited by 70
Codon-optimization in gene therapy: promises, prospects and challenges
Paremskaia, A. I., Kogan, A. A., Murashkina, A., Naumova, D. A., Satish, A., Abramov, I. S., Feoktistova, S. G., Mityaeva, O. N., Deviatkin, A. A., & Volchkov, P. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1371596 · Cited by 79
Functional roles of the membrane-associated AAV protein MAAP
Galibert, L., Hyvönen, A., Eriksson, R. A. E., Mattola, S., Aho, V., Salminen, S., Albers, J., Peltola, S. K., Weman, S., Nieminen, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01220-7 · Cited by 66
Herzog, R. W. (2015) · Frontiers in Bioscience · doi:10.2741/4324 · Cited by 55
Adenoviromics: Mining the Human Adenovirus Species D Genome
Ismail, A. M., Lee, J. S., Lee, J. Y., Singh, G., Dyer, D. W., Seto, D., Chodosh, J., & Rajaiya, J. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02178 · Cited by 57
Nance, M. E., & Duan, D. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.107 · Cited by 51
Chandler, L. C., Barnard, A. R., Caddy, S. L., Patrício, M. I., McClements, M. E., Fu, H., Rada, C., MacLaren, R. E., & Xue, K. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.012 · Cited by 50
“It should be noted that a previous study using a much higher concentration of CQ (at 100 mM, compared with up to 12 mM in this study) showed a reduction in AAV2 transduction in a human hepatocellular carcinoma cell line.(33) The difference may be the result of the CQ concentrations used, e.”
ResultChandler, L., Yusuf, I., McClements, M., Barnard, A., MacLaren, R., & Xue, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144972 · Cited by 49
The curious case of AAV immunology
Keeler, A. M., Zhan, W., Ram, S., Fitzgerald, K. A., & Gao, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.037 · Cited by 53
Huang, L., Wan, J., Wu, Y., Tian, Y., Yao, Y., Yao, S., Ji, X., Wang, S., Su, Z., & Xu, H. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119142 · Cited by 48
Efficient capsid antigen presentation from adeno-associated virus empty virions in vivo
Pei, X., Earley, L. F., He, Y., Chen, X., Hall, N. E., Samulski, R. J., & Li, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00844 · Cited by 35
Self-citationSingle-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity
Wu, F., Luo, S., Zhang, Y., Ou, Y., Wang, H., Guo, Z., He, C., Bai, S., He, P., Jiang, M., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.07.004 · Cited by 36
An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs
Sun, J., Shao, W., Chen, X., Merricks, E. P., Wimsey, L., Abajas, Y. L., Niemeyer, G. P., Lothrop, C. D., Monahan, P. E., Samulski, R. J., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.07.011 · Cited by 30
Self-citationHe, Y., Weinberg, M. S., Hirsch, M., Johnson, M. C., Tisch, R., Samulski, R. J., & Li, C. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.065 · Cited by 26
Self-citationGene Therapy for Hemophilia: Progress to Date
Chapin, J. C., & Monahan, P. E. (2017) · BioDrugs · doi:10.1007/s40259-017-0255-0 · Cited by 26
Chai, Z., Zhang, X., Dobbins, A., Rigsbee, K. M., Wang, B., Samulski, R., & Li, C.-W. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.233 · Cited by 22
Self-citationEvaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models
Markusic, D. M., Nichols, T. C., Merricks, E. P., Palaschak, B., Zolotukhin, I., Marsic, D., Zolotukhin, S., Srivastava, A., & Herzog, R. W. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1200-1 · Cited by 19
Inhibition of antigen presentation during AAV gene therapy using virus peptides
Shao, W., Chen, X., Samulski, R. J., Hirsch, M. L., & Li, C. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddx427 · Cited by 17
Self-citationKistner, A., Chichester, J. A., Wang, L., Calcedo, R., Greig, J. A., Cardwell, L. N., Wright, M. C., Couthouis, J., Sethi, S., McIntosh, B. E., et al. (2023) · Gene Therapy · doi:10.1038/s41434-023-00423-z · Cited by 13
Zubkova, E., Beloglazova, I. B., Ratner, E. I., Dyikanov, D. T., Дергилев, К. В., Menshikov, M. Y., & Parfyonova, Y. V. (2021) · Biology Open · doi:10.1242/bio.058461 · Cited by 12
Advances in designing Adeno-associated viral vectors for development of anti-HBV gene therapeutics
Mnyandu, N., Limani, S. W., Arbuthnot, P. B., & Maepa, M. B. (2021) · Virology Journal · doi:10.1186/s12985-021-01715-9 · Cited by 9
Temporal insights into molecular and cellular responses during rAAV production in HEK293T cells
Patra, A. T., Tan, E., Kok, Y. J., Ng, S. K., & Bi, X. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101278 · Cited by 8
Adeno-associated Virus as a Mammalian DNA Vector
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015) · ASM Press eBooks · doi:10.1128/9781555819217.ch37 · Cited by 5
Self-citationRajapaksha, I. G., Angus, P., & Herath, C. B. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.80317 · Cited by 7
Pei, X., Han, M., & Zhang, L. (2019) · Blood Science · doi:10.1097/bs9.0000000000000030 · Cited by 4
Guapo, F., Donohue, N., Strasser, L., Boi, S., Füssl, F., Rainbow-Fletcher, A., Getty, P., Anderson, I., Barron, N., & Bones, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052785 · Cited by 4
Guo, P., Yu, C., Wang, Q., Zhang, R., Meng, X., & Feng, Y. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.04.004 · Cited by 6
Strategies for Evading Cellular Immunity Against Recombinant AAV Vectors in Gene Therapy
Wang, Z., Wu, X., Fu, D.-Y., Li, X., Liu, D., Liu, S., Zhao, Q., & Wang, H. (2026) · Current Medical Science · doi:10.1007/s11596-026-00178-9 · Cited by 2
Upregulation of CD8+ regulatory T cells following liver-directed AAV gene therapy
Gaddie, C. D., Senior, K. G., Chan, C. T., Hoffman, B. E., & Keeler, G. D. (2024) · Cellular Immunology · doi:10.1016/j.cellimm.2024.104806 · Cited by 2
Challenges in Humoral Immune Response to Adeno-Associated Viruses Determination
Naumova, D. A., Krokunova, T., Maksimov, D. O., Mityaeva, O. N., Astakhova, E. A., & Volchkov, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020816 · Cited by 3
Lin, N., Mavropoulos, S., & Ishikawa, K. (2026) · Human Gene Therapy · doi:10.1177/10430342261462309 · Cited by 1
Ghenassia, A. (2015) · theses.fr (ABES) · doi:10.70675/258b493cz74a9z4788zbbb4za8046cd94fe0 · Cited by 2
Intracellular fate of AAV particles in human Dendritic Cell and impact on Gene Transfer
Rossi, A. (2016) · theses.fr (ABES) · doi:10.70675/4518d4eazdbd8z4f46z96e2zf87942913c70
Nicolson, S. C. (2014) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/gbv4-z740
Self-citationQuantifying tagged mRNA export flux via nuclear pore complexes in single live cells
Jing, Y., Lv, Y., Ye, J., Yao, L., Chen, L., Mi, L., Fei, Y., Yu, Y., Dong, B., Lv, H., et al. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.01.049
Introduction to AAV ‐based in vivo Gene Therapy
Segurado, O. G. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch1
Caractérisation et immunomodulation de la réponse cellulaire contre les produits de thérapie génique
Avenel, A. (2024) · theses.fr (ABES) · doi:10.70675/f4cd9ee5z09e6z4e26z8edazf0770a51f57c
Carpentier, M. (2013) · theses.fr (ABES) · doi:10.70675/fa69ca30zf46az45f1z9638z003bd41555e4
Chassagne, J. (2019) · theses.fr (ABES) · doi:10.70675/74df0299z4167z4397zb93fz28bc889326f4
Intracellular trafficking and nuclear compartmentalization of AAV gene delivery
Hutchinson, T. E., Singh, R. E., Oliver, J. Y., Davis, A., Potter, M., Hsi, J., Mietzsch, M., Bennett, A. D., & McKenna, R. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201770
Son, Y.-W., Do, M., Cho, M., Kim, J., Kim, J. S., Lee, S.-W., Lee, H., Kim, J., Suh, W., Kim, S.-H., et al. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103435
Metadata
- Authors
- Li, C., He, Y., Nicolson, S., Hirsch, M., Weinberg, M. S., Zhang, P., Kafri, T., & Samulski, R. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Venue
- Journal of Clinical Investigation
- Published
- 2013-02-01
- Volume
- 123
- Issue
- 3
- Pages
- 1390-1401
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3582142
- OpenAlex
- W1997567318
- Cited by
- 61
- References
- 59
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 6 · 2023: 3 · 2022: 2 · 2021: 7 · 2020: 4 · 2019: 9 · 2018: 4 · 2017: 5 · 2016: 1 · 2015: 5 · 2014: 7 · 2013: 2
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health (5u54ar056953-05, 5U54AR056953)
- National Cancer Institute (P30CA016086)
- National Institute of Allergy and Infectious Diseases (R01AI072176, R01AI080726)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK084033)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (5U54AR056953, U54-AR056953)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, endosomal escape, cytotoxic T lymphocytes, proteasome inhibitors, nuclear localization signal, gene therapy vectors
- MeSH terms
- Dependovirus, Aminopeptidases, Animals, Antigens, Viral, Antiviral Agents, Chlorocebus aethiops, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases, Humans, Mice, Transgenic, Endosomes, Serine Endopeptidases, Transduction, Genetic, Genetic Therapy, Antigen Presentation, Virus Assembly, COS Cells, Nuclear Localization Signals, Brefeldin A, Protein Transport, Capsid Proteins, Cross-Priming, Proteasome Endopeptidase Complex, Mice, HEK293 Cells, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.